ZIOPHARM Oncology (NASDAQ:ZIOP) Trading 5.5% Higher

Shares of ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) traded up 5.5% during trading on Tuesday . The stock traded as high as $4.55 and last traded at $4.43. 2,494,502 shares traded hands during mid-day trading, an increase of 59% from the average session volume of 1,572,972 shares. The stock had previously closed at $4.20.

Several analysts recently commented on the stock. BidaskClub downgraded shares of ZIOPHARM Oncology from a “strong-buy” rating to a “buy” rating in a research report on Tuesday. Lake Street Capital started coverage on shares of ZIOPHARM Oncology in a research report on Thursday, April 4th. They issued a “buy” rating and a $7.00 price target for the company. Zacks Investment Research downgraded shares of ZIOPHARM Oncology from a “buy” rating to a “hold” rating in a research report on Saturday, May 18th. HC Wainwright restated a “buy” rating and set a $5.50 price objective on shares of ZIOPHARM Oncology in a research report on Thursday, May 9th. Finally, Laidlaw started coverage on shares of ZIOPHARM Oncology in a research report on Monday, April 1st. They set a “buy” rating and a $7.50 price objective for the company. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $5.75.

The company has a current ratio of 8.89, a quick ratio of 8.89 and a debt-to-equity ratio of 0.01. The firm has a market cap of $718.97 million, a PE ratio of -10.88 and a beta of 2.52.

ZIOPHARM Oncology (NASDAQ:ZIOP) last announced its quarterly earnings results on Wednesday, May 8th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.09) by $0.01. Analysts expect that ZIOPHARM Oncology Inc. will post -0.3 earnings per share for the current year.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Harel Insurance Investments & Financial Services Ltd. acquired a new stake in shares of ZIOPHARM Oncology during the 1st quarter worth about $35,000. Amalgamated Bank acquired a new stake in shares of ZIOPHARM Oncology during the 4th quarter worth about $37,000. Magnus Financial Group LLC acquired a new stake in shares of ZIOPHARM Oncology during the 1st quarter worth about $39,000. SG Americas Securities LLC acquired a new stake in shares of ZIOPHARM Oncology during the 4th quarter worth about $46,000. Finally, Legal & General Group Plc boosted its stake in shares of ZIOPHARM Oncology by 30.6% during the 4th quarter. Legal & General Group Plc now owns 25,865 shares of the biotechnology company’s stock worth $48,000 after purchasing an additional 6,054 shares during the last quarter. 38.51% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: This report was posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this report on another site, it was copied illegally and reposted in violation of international trademark and copyright law. The correct version of this report can be read at https://sportsperspectives.com/2019/06/13/ziopharm-oncology-nasdaqziop-trading-5-5-higher.html.

About ZIOPHARM Oncology (NASDAQ:ZIOP)

ZIOPHARM Oncology, Inc, a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Sleeping Beauty (SB), which is based on the genetic engineering of immune cells using a non-viral transposon/transposase system to reprogram T-cells outside of the body for infusion; and Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to attack cancer cells.

Further Reading: What is Depreciation?

Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.